Kerrisdale Advisers LLC Takes Position in Establishment Labs Holdings Inc. $ESTA

Kerrisdale Advisers LLC bought a new stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 20,390 shares of the company’s stock, valued at approximately $1,750,000. Kerrisdale Advisers LLC owned 0.07% of Establishment Labs at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of ESTA. BlackRock Inc. acquired a new stake in Establishment Labs in the second quarter worth about $135,752,000. William Blair Investment Management LLC acquired a new position in Establishment Labs during the 2nd quarter valued at about $61,273,000. Bank of America Corp DE bought a new stake in shares of Establishment Labs during the 2nd quarter worth about $52,176,000. Rice Hall James & Associates LLC bought a new stake in shares of Establishment Labs during the 2nd quarter worth about $48,134,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Establishment Labs by 117.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after buying an additional 438,206 shares in the last quarter. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Stock Performance

Shares of ESTA opened at $70.64 on Monday. The company has a 50-day moving average of $85.00 and a two-hundred day moving average of $74.94. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -53.92 and a beta of 1.07. The company has a debt-to-equity ratio of 12.11, a current ratio of 3.84 and a quick ratio of 2.52. Establishment Labs Holdings Inc. has a one year low of $36.53 and a one year high of $97.59.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The company had revenue of $67.54 million during the quarter, compared to analyst estimates of $65.79 million. Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. The firm’s quarterly revenue was up 31.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.57) EPS. On average, equities research analysts expect that Establishment Labs Holdings Inc. will post -1.15 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Citigroup upgraded shares of Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price objective for the company in a report on Thursday, August 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Mizuho upped their price objective on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Needham & Company LLC lifted their target price on Establishment Labs from $86.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, BTIG Research boosted their price target on shares of Establishment Labs from $96.00 to $103.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Establishment Labs currently has an average rating of “Moderate Buy” and an average price target of $100.25.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.